129 related articles for article (PubMed ID: 30334671)
1. Aurora kinase B siRNA-loaded lactoferrin nanoparticles potentiate the efficacy of temozolomide in treating glioblastoma.
Kumari S; Bhattacharya D; Rangaraj N; Chakarvarty S; Kondapi AK; Rao NM
Nanomedicine (Lond); 2018 Oct; 13(20):2579-2596. PubMed ID: 30334671
[TBL] [Abstract][Full Text] [Related]
2. Overcoming blood brain barrier with a dual purpose Temozolomide loaded Lactoferrin nanoparticles for combating glioma (SERP-17-12433).
Kumari S; Ahsan SM; Kumar JM; Kondapi AK; Rao NM
Sci Rep; 2017 Jul; 7(1):6602. PubMed ID: 28747713
[TBL] [Abstract][Full Text] [Related]
3. A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.
Kim SS; Rait A; Kim E; Pirollo KF; Chang EH
Nanomedicine; 2015 Feb; 11(2):301-11. PubMed ID: 25240597
[TBL] [Abstract][Full Text] [Related]
4. Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells.
Paul-Samojedny M; Pudełko A; Kowalczyk M; Fila-Daniłow A; Suchanek-Raif R; Borkowska P; Kowalski J
BioDrugs; 2016 Apr; 30(2):129-44. PubMed ID: 26902608
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo effect of human lactoferrin on glioblastoma growth.
Arcella A; Oliva MA; Staffieri S; Aalberti S; Grillea G; Madonna M; Bartolo M; Pavone L; Giangaspero F; Cantore G; Frati A
J Neurosurg; 2015 Oct; 123(4):1026-35. PubMed ID: 26186026
[TBL] [Abstract][Full Text] [Related]
6. Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.
Toren A; Pismenyuk T; Yalon M; Freedman S; Simon AJ; Fisher T; Moshe I; Reichardt JK; Constantini S; Mardor Y; Last D; Guez D; Daniels D; Assoulin M; Mehrian-Shai R
Oncotarget; 2016 Nov; 7(46):74860-74871. PubMed ID: 27556862
[TBL] [Abstract][Full Text] [Related]
7. Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells.
Kim JS; Shin DH; Kim JS
J Control Release; 2018 Jan; 269():245-257. PubMed ID: 29162480
[TBL] [Abstract][Full Text] [Related]
8. Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.
Kim SS; Rait A; Kim E; DeMarco J; Pirollo KF; Chang EH
Cancer Lett; 2015 Dec; 369(1):250-8. PubMed ID: 26325605
[TBL] [Abstract][Full Text] [Related]
9. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
10. The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells.
Xu Y; Shen M; Li Y; Sun Y; Teng Y; Wang Y; Duan Y
Oncotarget; 2016 Apr; 7(15):20890-901. PubMed ID: 26956046
[TBL] [Abstract][Full Text] [Related]
11. Combination treatment with theranostic nanoparticles for glioblastoma sensitization to TMZ.
Yoo B; Ifediba MA; Ghosh S; Medarova Z; Moore A
Mol Imaging Biol; 2014 Oct; 16(5):680-9. PubMed ID: 24696184
[TBL] [Abstract][Full Text] [Related]
12. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
13. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Berenguer-Daizé C; Astorgues-Xerri L; Odore E; Cayol M; Cvitkovic E; Noel K; Bekradda M; MacKenzie S; Rezai K; Lokiec F; Riveiro ME; Ouafik L
Int J Cancer; 2016 Nov; 139(9):2047-55. PubMed ID: 27388964
[TBL] [Abstract][Full Text] [Related]
14. Enhanced Efficacy of Temozolomide Loaded by a Tetrahedral Framework DNA Nanoparticle in the Therapy for Glioblastoma.
Fu W; You C; Ma L; Li H; Ju Y; Guo X; Shi S; Zhang T; Zhou R; Lin Y
ACS Appl Mater Interfaces; 2019 Oct; 11(43):39525-39533. PubMed ID: 31601097
[TBL] [Abstract][Full Text] [Related]
15. Rutin increases the cytotoxicity of temozolomide in glioblastoma via autophagy inhibition.
Zhang P; Sun S; Li N; Ho ASW; Kiang KMY; Zhang X; Cheng YS; Poon MW; Lee D; Pu JKS; Leung GKK
J Neurooncol; 2017 May; 132(3):393-400. PubMed ID: 28293765
[TBL] [Abstract][Full Text] [Related]
16. Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide.
Johannessen TC; Hasan-Olive MM; Zhu H; Denisova O; Grudic A; Latif MA; Saed H; Varughese JK; Røsland GV; Yang N; Sundstrøm T; Nordal A; Tronstad KJ; Wang J; Lund-Johansen M; Simonsen A; Janji B; Westermarck J; Bjerkvig R; Prestegarden L
Int J Cancer; 2019 Apr; 144(7):1735-1745. PubMed ID: 30289977
[TBL] [Abstract][Full Text] [Related]
17. Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy.
Song S; Mao G; Du J; Zhu X
Drug Deliv; 2016 May; 23(4):1404-8. PubMed ID: 26203687
[TBL] [Abstract][Full Text] [Related]
18. Silencing of ZFP36L2 increases sensitivity to temozolomide through G2/M cell cycle arrest and BAX mediated apoptosis in GBM cells.
Che Mat MF; Mohamad Hanif EA; Abdul Murad NA; Ibrahim K; Harun R; Jamal R
Mol Biol Rep; 2021 Feb; 48(2):1493-1503. PubMed ID: 33590411
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
20. APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line.
Montaldi AP; Godoy PR; Sakamoto-Hojo ET
Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():19-29. PubMed ID: 26520369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]